Florida teens may be blocked from birth control, STI treatment without parental consent
A bill entitled "Parental Rights" (SB 1288) by Sen. Erin Grall, R-Fort Pierce, which has passed through its first two committees, would nullify an existing state law that allows for a physician to prescribe birth control or STI treatment for those under 18.
But the American College of Obstetricians and Gynecologists (ACOG) supports 'confidential" care, as "it is even more crucial for adolescents because the lack of confidentiality can be a barrier to the delivery of reproductive health care services." This includes confidentiality in billing and insurance claims.
According to guidance provided by ACOG: 'Even though policies should encourage and facilitate communication between a minor and her parent or guardian when appropriate, legal barriers and deference to parental involvement should not stand in the way of needed contraceptive care for adolescents who request confidential services.'
Dr. Anne-Marie Amies Oelschlager, a professor of obstetrics and gynecology at the University of Washington, said based on her clinical experience, what patients tell her when their parents step out of the room is often different from what is said in front of them.
'I want to ask every single person in that (legislature) if they would call up their mother and tell their mother every single thing they've done sexually in their life,' Oelschlager told the USA TODAY NETWORK – Florida.
'It's not uncommon for adolescents to hold back information from their parents," she added. "It's part of respecting boundaries between a parent and a child.'
Grall stood by her position that if a child has an STI and needs treatment, a parent should know. A more hardline earlier version of the bill originally required parental consent for just STI testing, but lawmakers amended the bill, allowing minors to get tested for STIs without parental consent.
'I believe their needs can be best met with parenting. I get that it's hard, and I get that everything's not perfect, but it doesn't mean we say 'OK government, you can do better,' ' Grall said at a recent Senate committee meeting.
The bill would not prevent a minor from buying birth control or emergency contraception over the counter, like condoms or Plan B. It does, however, penalize with a misdemeanor charge any health care provider who prescribes birth control pills or related medication without a parent or guardian's consent.
'You could have a child that has HIV, and you would not be informed as a parent. You could have a child that has syphilis who needs certain types of treatment. That treatment could interact with other things that that child either has, a reaction to, an allergy to … and those are things that parents know. A provider may not know, and a parent should know when a child is getting treatment,' Grall said.
At the first committee hearing in the Senate, Grall said she did not consult with medical professionals when drafting the original policy.
From 2017 to 2021, syphilis rates rose 82% in Florida and increased 72% nationwide, according to the U.S. Centers for Disease Control. Congenital syphilis, which occurs when syphilis is passed to a baby during pregnancy, rose 88% in Florida during this time period, and 219% nationwide.
Chlamydia and gonorrhea are often asymptomatic, Oelschlager said, and left untreated can lead to life-changing consequences.
In women, untreated chlamydia and gonorrhea cause inflammation in the cervix, which can travel up into the uterus and into the fallopian tubes. Patients can get intense inflammation, infection and scarring from the untreated STIs. Oelschlager said she's had adolescent patients admitted to the hospital because of severe infections.
"I understand the need to want to make sure my children are healthy and safe, and I also want to know if they're in a dangerous situation or if they've been hurt, but also understand they're never going to tell me everything that they would tell their doctor about their private sexual lives,' Oelschlager said.
Ana Goñi-Lessan, state watchdog reporter for the USA TODAY Network – Florida, can be reached at agonilessan@gannett.com.
This article originally appeared on Tallahassee Democrat: Birth control and parental consent debated in Florida bill
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indianapolis Star
2 hours ago
- Indianapolis Star
Trump's tax bill snuck in Planned Parenthood attack that will hurt Indiana women
Reproductive health care is under attack, and recent policy changes threaten to make matters worse. The One Big Beautiful Bill Act, signed into law July 4, includes provisions that go into effect Oct. 1 mandating that Medicaid spending can't be used towards clinics designated as nonprofit organizations that provide family planning services and reproductive care. A federal judge has partially blocked implementation of this provision. If it takes effect, though, that would mean Medicaid users won't be able to access care from Planned Parenthood clinics, among other similar nonprofit health services. While conservatives are hailing this as a pro-life victory, this law is far from saving lives. It targets all of the resources and care that Planned Parenthood provides, including contraception, STI testing, HIV-related care, mental health support and so much more. More from Sadia Khatri: Abortion ban, fetal anomaly and a ticking clock: 'an impossible decision' There's a misconception that Planned Parenthood only provides access to abortions. The organization offers a wide variety of care. In states like Indiana, where abortion is banned, Planned Parenthood doesn't even provide abortions. Some states might use state funding to cover abortion services for Medicaid enrollees, but federal dollars do not pay for abortions. Dr. Tracey Wilkinson, a pediatrician and professor at the Indiana University School of Medicine, thinks the Big Beautiful Bill has less to do with fiscal responsibility and a lot more to do with control. 'The Hyde Amendment has been in place for decades, preventing any federal funds, including Medicaid funds, to ever be used for abortion,' Wilkinson said. 'This issue in the federal budget is not about that. This issue is about preventing people that want to get birth control or want to get testing for sexually transmitted diseases, not being able to go there anymore, and ultimately, hopefully, the goal being that that clinic no longer can keep their doors open and will close.' This bill goes beyond the typical anti-abortion agenda. It's an attack on health care, and it's particularly concerning for a state like Indiana. More from Sadia Khatri: Why young progressives shouldn't give up on Indiana — or flee from it Many Indiana counties are considered maternity care deserts, which are defined as counties where there are zero hospitals that offer obstetric care and zero physicians who provide obstetric care. A little under a quarter of Indiana counties are maternity care deserts. An additional fifth of Indiana counties have limited access to obstetric care. Collectively, almost half of the counties in Indiana have limited or no access to obstetric care. Not all Hoosiers can easily get access to reproductive, sexual health and general OB-GYN-related care in Indiana. This bill is only going to exacerbate that. Planned Parenthood last year received 34,403 visits from Hoosiers across 11 health centers, 53% of whom had incomes at or below the federal poverty line. In 35% of cases, patients were insured by Medicaid. Planned Parenthood provided 30,000 family planning visits, 42,000 STI tests, 5,500 HIV tests and 1,300 Pap tests. Federal law threatens all of those services for Medicaid enrollees. For Hoosiers on Medicaid who live in areas where obstetric care is limited or nonexistent, there aren't always alternatives to Planned Parenthood clinics. Planned Parenthood often is the alternative. It's not just Planned Parenthood that's going to be negatively impacted. Indiana could lose 12 rural hospitals, Wilkinson said. When hospitals shut down, health care deserts worsen. This allegedly big and beautiful bill is about taking bodily autonomy and control away from patients and placing it in the hands of elected officials. Limiting access to family-planning and contraceptive resources has ripple effects. 'When you take away people's abilities to decide if and when and how to become a parent, all the downstream impacts are worsened,' Wilkinson said. 'Infant mortality is worsened, maternal mortality is worsened and pregnancies tend to be more complicated.' For Hoosiers enrolled in Medicaid, it's important to be vigilant and aware about your coverage. Dr. Wilkinson recommends regularly checking to make sure you are still enrolled. Rebecca Gibron, a regional CEO for Planned Parenthood, said the organization will continue to build new pathways to care. Planned Parenthood recently increased access to its telehealth services, helping more patients access remote services. "Indiana's reproductive health care landscape is being reshaped by relentless political interference from local and national leaders —designed to limit our freedom to control our own bodies," Gibron said. "But they should know: Planned Parenthood will never stop showing up for our patients." Despite what some politicians and pundits may say about the Big Beautiful Bill, the reality is that people will lose access to healthcare in some way. The outlook on reproductive health in Indiana is only going to get more grim.
USA Today
14 hours ago
- USA Today
Phase 1 Clinical Ttrial of HIV Vaccine Starts in Africa to Evaluate Immune Responses to Highly Networked HIV T-Cell Epitopes
Led by a team of African researchers, first doses of the novel T cell-inducing GRAdHIVNE1 vaccine candidate have been given. HARARE, ZIMBABWE, ROME, ITALY, NEW YORK, NY, AND CAMBRIDGE, MA / ACCESS Newswire / August 4, 2025 / The Mutala Trust, ReiThera Srl (ReiThera), the Ragon Institute of Mass General Brigham, MIT, and Harvard (the Ragon Institute), and IAVI are pleased to announce that the first doses of an investigational HIV vaccine candidate have been administered. The vaccine candidate, Gorilla Adenovirus Vectored HIV Networked Epitopes Vaccine (GRAdHIVNE1), was first administered on July 28, 2025, at the Mutala Trust clinical trial site in Harare, Zimbabwe. This effort is made possible by a global collaboration and a team of African principal investigators who will lead the clinical research in South Africa and Zimbabwe (listed below). Vaccine immunogenicity will also be assessed locally by a network of state-of-the-art African research institutes: Cape Town HVTN Immunology Laboratory in Cape Town, African Health Research Institute in Durban, and the National Institute for Communicable Diseases in Johannesburg, South Africa. This Phase 1, first-in-human clinical trial will enroll approximately 120 healthy adults aged 18-50 years, including 48 people living with HIV who are virally suppressed on antiretroviral therapy (ART). The trial is designed to assess the safety and immunogenicity of the vaccine candidate in people living with and without HIV. Participants will receive either one or two doses of the investigational vaccine or a placebo and will be monitored over a period of 19 months for safety and immune responses. This clinical trial, IAVI C114, is sponsored by IAVI. GRAdHIVNE1 has been made possible by a collaborative effort. ReiThera developed the GRAd viral vector platform and manufactured the vaccine candidate, while the Ragon Institute designed the immunogen using novel strategies to identify protective HIV epitopes and facilitate their targeting by T cells. This clinical program is funded by the Gates Foundation. The IAVI C114 clinical trial is taking place at three clinical trial sites: the Mutala Trust Clinical Trial Site, in Harare, Zimbabwe; the Desmond Tutu Health Foundation (DTHF), in Cape Town, South Africa; and the Africa Health Research Institute (AHRI), in Durban, South Africa. To determine the vaccine candidate's potential for relevance in sub-Saharan Africa, where disease burden is greatest, it is essential that the candidate be tested within communities affected by the epidemic. 'This is a landmark moment for South Africa, Zimbabwe, and the continent. It shows the power of true partnership: IAVI's sponsorship, ReiThera's GRAd technology, the Ragon Institute's innovative immunogen built on decades of science, and African investigators co-leading every phase of the trial. We are edging closer to an HIV vaccine, made possible by global collaboration, with clinical trials conducted in Africa, for Africa, and for the world.' said Dr. Tariro Makadzange, Clinical Trial Lead, Mutala Trust. 'This trial represents the future of vaccine development, rooted in Africa, built through global partnerships, and designed for the communities most affected by HIV,' said Dr. Vincent Muturi-Kioi, HIV Vaccines Product Development Team Lead at IAVI. The vaccine candidate is designed to engage the immune system to recognize and target critical structural regions of HIV using a clinically validated, potent, T cell-inducing GRAd vector. This approach will be evaluated to assess the ability of the vaccine candidate to direct strong CD8+ T cell immune responses towards these vulnerable viral regions. 'We are thrilled to be moving insights from our long-term studies of spontaneous elite controllers of HIV toward the development of GRAdHIVNE1 and its testing in Africa. We are truly grateful to the network of global and African partners that have come together to make the IAVI C114 trial a reality,' said Dr. Gaurav Gaiha, Associate Professor of Medicine at Harvard Medical School and Principal Investigator at the Ragon Institute of Mass General Brigham, MIT, and Harvard. Because CD8+ T cells induced by this vaccine hold promise for targeting HIV-infected cells, this clinical trial will also assess the safety and immune response in people living with HIV. These data will be used to assess the suitability of the vaccine candidate for the development of investigational HIV therapeutic and curative interventions. 'We are enormously pleased with the launch of this Phase 1 trial representing the result of a successful global partnership,' said Stefano Colloca, CEO and co-Founder of ReiThera. 'This candidate HIV vaccine, built on our GRAd platform, holds great promise to trigger a strong CD8 response targeting vulnerable viral regions.' Principal Investigators Leading Clinical Trial Sites: Tariro Makadzange, Mutala Trust Theodorah Rirhandzu Ndzhukule, DTHF Limakatso Lebina, AHRI About IAVI IAVI is a global nonprofit scientific organization that works to develop vaccines and antibodies to prevent HIV and other infectious diseases, with a focus on innovation and equitable access. IAVI is the sponsor of this trial. Read more at IAVI media contact Heather Teixeira hteixeira@ About Mutala Trust Mutala Trust is founding member of Africa Clinical Research Network (ACRN) and is a site based in Harare, Zimbabwe. It is known for conducting high-quality, ethically sound clinical trials addressing diseases that affect African communities. Mutala is the clinical lead site for the study. Mutala Trustmedia contact coms@ About ReiThera Srl. ReiThera Srl, an Italian CDMO specializing in technology and process development as well as GMP manufacturing of viral vectors for genetic vaccines and advanced therapies, is the developer and owner of the GRAd platform used for this HIV vaccine. ReiThera media contact communication@ About the Ragon Institute of Mass General Brigham, MIT, and Harvard The Ragon Institute of Mass General Brigham, MIT, and Harvard was established with a collaborative scientific mission among these institutions that brings scientists, clinicians and engineers together to harness the immune system to combat and cure human disease. They contributed to vaccine design. For more information, visit Ragon Institutemedia contact ragoncommunications@ SOURCE: IAVI View the original press release on ACCESS Newswire
The Hill
15 hours ago
- The Hill
RFK Jr. ‘reviewing' ouster of preventive task force members
Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. said Monday he is 'reviewing' whether to remove all members of an influential advisory committee that offers guidance about preventive health services. The U.S. Preventive Services Task Force is composed of medical experts who serve four-year terms on a volunteer basis. They are appointed by the HHS secretary and are supposed to be shielded from political influence. The task force reviews reams of scientific evidence to make recommendations on services such as cancer screenings, HIV prevention medications and more. It makes its recommendations using a grading scale, and ObamaCare requires insurers to cover services the task force recommends with a 'grade' of A or B at no cost to patients. The Wall Street Journal first reported late last month that Kennedy was considering firing the panelists because they were too 'woke.' During a press conference about the Supplemental Nutrition Assistance Program (SNAP), Kennedy did not deny that removing the members of the task force was under consideration. 'The task force has done very little over the past five years, and we want to make sure it is performing, and it is approving interventions that are actually going to prevent the health decline of the American public. And it hasn't,' he said. 'We're looking at the personnel and we're making the decision now, but no decision has been made.' Kennedy's office abruptly postponed the July meeting of the task force, alarming some Democrats and public health leaders. The discussion on removing the entire task force comes on the heels of a Supreme Court decision in June originally focused on a recommendation to cover certain HIV-prevention drugs. The ruling asserted Kennedy has the power to hire and dismiss panelists at will, as well as to potentially delay or veto the recommendations they issue — something no prior administration has done.
